Multiple interleukin-1β-converting enzymes contribute to inflammatory arthritis

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3524-3530

  Stehlik, Christian ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; B CELL ACTIVATING FACTOR; BLYS; CATHEPSIN G; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GELATINASE A; GELATINASE B; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; LEUKOCYTE ELASTASE; LYMPHOTOXIN BETA; METHOTREXATE; MYELOBLASTIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALAZOSULFAPYRIDINE; SERINE PROTEINASE INHIBITOR; STROMELYSIN; TOCILIZUMAB; UNCLASSIFIED DRUG; VE 13 045; CHYMASE; INTERLEUKIN 1; INTERLEUKIN 1 PRECURSOR; PROTEIN PRECURSOR; PROTEINASE;

ARTHRITIS; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; ENZYME ACTIVITY; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; ANIMAL; DISEASE MODEL; ENZYME ACTIVATION; ENZYMOLOGY; IMMUNOLOGY; MACROPHAGE; MAST CELL; METABOLISM; MOUSE; NEUTROPHIL; NOTE;

ANIMALS; ARTHRITIS, RHEUMATOID; CASPASE 1; CHYMASES; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; ENZYME ACTIVATION; INTERLEUKIN-1; LEUKOCYTE ELASTASE; MACROPHAGES; MAST CELLS; MICE; MYELOBLASTIN; NEUTROPHILS; PROTEIN PRECURSORS;

EID: 73349114937     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24961     Document Type: Editorial

References (50)

1. Joosten LA, Netea MG, Fantuzzi G, Koenders MI, Helsen MM, Sparrer H, et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β. Arthritis Rheum 2009;60: 3651-62.
2. Guma M, Ronacher L, Liu-Bryan R, Takai S, Karin M, Corr M. Caspase 1-independent activation of interleukin-1β in neutrophilpredominant inflammation. Arthritis Rheum 2009;60:3642-50.
3. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45.
4. Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adultonset Still's disease. Arthritis Rheum 2005;52:1794-803.
5. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
6. De Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler syndrome: beyond the case reports. Review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007;37:137-48.
7. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9: R28-35.
8. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflamma-tion of acute or chronic tophaceous gout with anakinra. Ann Rheum Dis 2007;66:1683-4.
9. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008;58:631-3.
10. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586-99.
11. Van de Loo AA, van den Berg WB. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-45.
12. Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A 1986;83:8749-53.
13. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-9.
14. Fong KY, Boey ML, Koh WH, Feng PH. Cytokine concentrations in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions. Clin Exp Rheumatol 1994;12:55-8.
15. Van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000;59 Suppl 1:i81-4.
16. Campbell IK, O'Donnell K, Lawlor KE, Wicks IP. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001;107:1519-27.
17. Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum 2002;46:533-44.
18. Ku G, Faust T, Lauffer LL, Livingston DJ, Harding MW. Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 1996;8:377-86.
19. Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:1798-805.
20. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
21. Nicklin MJ, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-12.
22. Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford) 2004;43 Suppl 3:iii10-6.
23. Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992; 356:768-74.
24. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Van Ness K, Greenstreet TA, et al. Molecular cloning of the interleukin-1β converting enzyme. Science 1992;256:97-100.
25. Black RA, Kronheim SR, Cantrell M, Deeley MC, March CJ, Prickett KS, et al. Generation of biologically active interleukin-1β by proteolytic cleavage of the inactive precursor. J Biol Chem 1988;263:9437-42.
26. Hazuda DJ, Strickler J, Kueppers F, Simon PL, Young PR. Processing of precursor interleukin 1β and inflammatory disease. J Biol Chem 1990;265:6318-22.
27. Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H, et al. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A 1999;96:6261-6.
28. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 2007;130: 918-31.
29. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1β (IL-1β) to an active IL-1 species by human mast cell chymase. J Exp Med 1991;174:821-5.
30. Irmler M, Hertig S, MacDonald HR, Sadoul R, Becherer JD, Proudfoot A, et al. Granzyme A is an interleukin 1β-converting enzyme. J Exp Med 1995;181:1917-22.
31. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol 1998;161:3340-6.
32. Matsushima K, Taguchi M, Kovacs EJ, Young HA, Oppenheim JJ. Intracellular localization of human monocyte associated interleukin 1 (IL 1) activity and release of biologically active IL 1 from monocytes by trypsin and plasmin. J Immunol 1986;136:2883-91.
33. Nylander-Lundqvist E, Egelrud T. Formation of active IL-1β from pro-IL-1β catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm Venereol 1997;77:203-6.
34. Dinarello CA, Cannon JG, Mier JW, Bernheim HA, LoPreste G, Lynn DL, et al. Multiple biological activities of human recombinant interleukin 1. J Clin Invest 1986;77:1734-9.
35. Cameron P, Limjuco G, Rodkey J, Bennett C, Schmidt JA. Amino acid sequence analysis of human interleukin 1 (IL-1): evidence for biochemically distinct forms of IL-1. J Exp Med 1985;162:790-801.
36. Wewers MD. IL-1β: an endosomal exit. Proc Natl Acad Sci U S A 2004;101:10241-2.
37. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. Mol Cell 2002;10:417-26.
38. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-65.
39. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
40. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biol Chem 2007;388:1141-9.
41. Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001;167:1601-8.
42. Nigrovic PA, Binstadt BA, Monach PA, Johnsen A, Gurish M, Iwakura Y, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A 2007;104:2325-30.
43. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002;297:1689-92.
44. Corr M, Crain B. The role of FcγR signaling in the K/B x N serum transfer model of arthritis. J Immunol 2002;169:6604-9.
45. Hu Y, Pham CT. Dipeptidyl peptidase I regulates the development of collagen-induced arthritis. Arthritis Rheum 2005;52:2553-8.
46. Sugawara S, Uehara A, Nochi T, Yamaguchi T, Ueda H, Sugiyama A, et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 2001; 167:6568-75.
47. Dai SM, Shan ZZ, Xu H, Nishioka K. Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis 2007;66:1411-8.
48. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009;106:9021-6.
49. Rosengren S, Hoffman HM, Bugbee W, Boyle DL. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 2005;64:708-14.
50. Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:1216-25.